Join our GeneTex webinar series on
Blood plasma-derived extracellular vesicles: A minimally invasive tool for predicting response to cancer treatment on Tuesday, Nov 29, 2022, at 08:30 p.m. (IST)
Extracellular vesicles (EVs), including exosomes and microvesicles, are nanosized structures released in the extracellular space. EVs are released by many cell types, are present in all body fluids, and are involved in intercellular communications. EVs embody the status of the producer cells. Thus, they may serve as i) indicators of health or disease states, ii) minimally invasive biomarkers for disease diagnosis, or iii) predictors of therapeutic response. Despite the importance of EVs, current EV isolation methods have limitations. Dr. Okeoma’s webinar will describe how her lab developed particle purification liquid chromatography (PPLC) as a superior EV isolation tool and applied it to discover that circulating blood plasma-derived EVs (BEVs) hold promise as minimally invasive biomarkers for predicting response to neoadjuvant chemotherapy in patients with breast cancer. Her findings directly relate to the clinical management of breast cancer and other malignancies.
Speaker: Chioma M. Okeoma, Ph.D.,
Dr. Okeoma is Professor and Vice Chair of Research, Department of Pathology, Microbiology, and Immunology, School of Medicine at New York Medical College (NYMC) Valhalla, NY, and a Fellow of the Lovelace Biomedical Research Institute, Albuquerque, NM.